Litcius/Paper detail

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

Emma Wall, Mary Wu, Ruth Harvey, Gavin Kelly, Scott Warchal, Chelsea Sawyer, Rodney S. Daniels, Philip Hobson, Emine Hatipoglu, Yenting Ngai, Saira Hussain, Jérôme Nicod, Robert Goldstone, Karen Ambrose, Steve Hindmarsh, Rupert Beale, Andrew Riddell, Steve Gamblin, Michael Howell, George Kassiotis, Vincenzo Libri, Bryan Williams, Charles Swanton, Sonia Gandhi, David L.V. Bauer

2021The Lancet559 citationsDOIOpen Access PDF

Topics & Concepts

Spike ProteinSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VaccinationMedicinePopulationCoronavirus disease 2019 (COVID-19)VirologyMutationLineage (genetic)GeneticsBiologyGeneEnvironmental healthInfectious disease (medical specialty)PathologyDiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination | Litcius